{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T17:45:11Z","timestamp":1774633511095,"version":"3.50.1"},"reference-count":22,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003395","name":"Scientific Research Innovation Program of Shanghai Municipal Education Commission","doi-asserted-by":"publisher","award":["2023FGS2"],"award-info":[{"award-number":["2023FGS2"]}],"id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>In this study, twenty-four new furoxan and seco-coumarin hybrids were synthesized, and their antiproliferative activities against four breast cancer cells (MCF-7\/ADR, MCF-7, MDA-MB-231, and MDA-MB-468) were evaluated. Among them, compound 9e exhibited significant toxicity against MCF-7\/ADR cells compared to MCF-7 cells, with a 1401-fold increase, indicating its high collateral sensitivity. Meanwhile, 9e exhibited relatively lower toxicity to normal cell lines and improved solubility compared to the previous active compound, 4A93, which features a coumarin integrity core. Preliminary pharmacological studies revealed that 9e might be a potential P-glycoprotein substrate, which enters the lysosomes of MCF-7\/ADR to release effective concentrations of nitric oxide, producing reactive oxygen species and inducing apoptosis. Moreover, laser confocal microscopy and Western Blot experiments showed that 9e could induce autophagy in MCF-7\/ADR cells. Additionally, the anti-tumor activity of compound 9e could be inhibited by the ferroptosis inhibitor Fer-1. These results suggest that the remarkable antiproliferative potency of these hybrids in MCF-7\/ADR may be related to multiple anticancer mechanisms. As a novel nitric oxide donor, compound 9e was used to explore the potential development of an anti-tumor candidate with special pharmacological mechanisms to overcome multidrug resistance in breast cancer.<\/jats:p>","DOI":"10.3390\/molecules30112341","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T09:29:36Z","timestamp":1748338176000},"page":"2341","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Synthesis and Biological Evaluation of Seco-Coumarin\/Furoxan Hybrids as Potent Anti-Tumor Agents to Overcome Multidrug Resistance via Multiple Mechanisms"],"prefix":"10.3390","volume":"30","author":[{"given":"Feng","family":"Qu","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiachen","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201203, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiufan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuquan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"La","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuqin","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3975-8196","authenticated-orcid":false,"given":"Hongrui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201203, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8197-3108","authenticated-orcid":false,"given":"Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Subhan, M.A., and Torchilin, V.P. (2023). Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15041242"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Jacobs, A.T., Castaneda-Cruz, D.M., Rose, M.M., and Connelly, L. (2022). Targeted therapy for breast cancer: An overview of drug classes and outcomes. Biochem. Pharmacol., 204.","DOI":"10.1016\/j.bcp.2022.115209"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1002\/cncr.33102","article-title":"Novel HER2-targeted therapies for HER2-positive metastatic breast cancer","volume":"126","author":"Kunte","year":"2020","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Bukowski, K., Kciuk, M., and Kontek, R. (2020). Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093233"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12943-022-01524-w","article-title":"CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1\/P-gp mediated multi-drug resistance (MDR) in cancer cells","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Dong, X.D., Zhang, M., Cai, C.Y., Teng, Q.X., Wang, J.Q., Fu, Y.G., Cui, Q., Patel, K., Wang, D.T., and Chen, Z.S. (2022). Overexpression of ABCB1 Associated with the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.843829"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1007\/s00204-020-02793-4","article-title":"Human multidrug resistance protein 4 (MRP4) is a cellular efflux transporter for paracetamol glutathione and cysteine conjugates","volume":"94","author":"Koenderink","year":"2020","journal-title":"Arch. Toxicol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1074\/jbc.M116.772699","article-title":"Tumor stressors induce two mechanisms of intracellular P-glycoprotein-mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones","volume":"293","author":"Bae","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9588","DOI":"10.1074\/jbc.M114.631283","article-title":"Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp)","volume":"290","author":"Jansson","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.freeradbiomed.2008.03.020","article-title":"The chemical biology of nitric oxide: Implications in cellular signaling","volume":"45","author":"Thomas","year":"2008","journal-title":"Free Radic. Biol. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.niox.2019.09.005","article-title":"Nitric oxide and its derivatives in the cancer battlefield","volume":"93","author":"Kamm","year":"2019","journal-title":"Nitric Oxide"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrc1910","article-title":"The role of nitric oxide in tumour progression","volume":"6","author":"Fukumura","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1021\/cr000040l","article-title":"Nitric oxide donors: Chemical activities and biological applications","volume":"102","author":"Wang","year":"2002","journal-title":"Chem. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1002\/ejoc.201900622","article-title":"Renaissance of 1,2,5-Oxadiazolyl Diazonium Salts: Synthesis and Reactivity","volume":"2019","author":"Zhilin","year":"2019","journal-title":"Eur. J. Org. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/jcmm.12796","article-title":"Anticancer efficacy of a nitric oxide-modified derivative of bifendate against multidrug-resistant cancer cells","volume":"20","author":"Ren","year":"2016","journal-title":"J. Cell Mol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9343","DOI":"10.1021\/jm500613m","article-title":"Hybrids of phenylsulfonylfuroxan and coumarin as potent antitumor agents","volume":"57","author":"Liu","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9328","DOI":"10.1021\/acs.jmedchem.2c00608","article-title":"Novel Hybrids of 3-Substituted Coumarin and Phenylsulfonylfuroxan as Potent Antitumor Agents with Collateral Sensitivity against MCF-7\/ADR","volume":"65","author":"Yu","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1021\/acsmedchemlett.8b00125","article-title":"Novel Nitric Oxide Donors of Phenylsulfonylfuroxan and 3-Benzyl Coumarin Derivatives as Potent Antitumor Agents","volume":"9","author":"Guo","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"115218","DOI":"10.1016\/j.ejmech.2023.115218","article-title":"Design, synthesis and biological evaluation of seco-DSP\/DCK derivatives reversing P-glycoprotein-mediated paclitaxel resistance in A2780\/T cells","volume":"250","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Helliwell, M.V., Zhang, Y., El Harchi, A., Dempsey, C.E., and Hancox, J.C. (2023). Inhibition of the hERG Potassium Channel by a Methanesulphonate-Free E-4031 Analogue. Pharmaceuticals, 16.","DOI":"10.3390\/ph16091204"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/11\/2341\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:41:31Z","timestamp":1760031691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/11\/2341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["molecules30112341"],"URL":"https:\/\/doi.org\/10.3390\/molecules30112341","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]}}}